

Solving Kids' Cancer™ Executive Biographies

Scott Kennedy Executive Director & Co-Founder

Scott co-founded SKC in 2007 as a tribute to his son, Hazen Kennedy, who was diagnosed with neuroblastoma at age 3. Hazen was Scott's inspiration for creating Solving Kids' Cancer in part because Hazen wanted to become a scientist when he grew up in order to help people by creating new medicines.

As Executive Director, Scott Kennedy is involved in all aspects of SKC, from managing operational staff and fundraising to policy development and fiscal management. He is integrally involved in the identification, funding, and management of the organization's scientific programs.

Before co-founding SKC, Scott worked in marketing at CDW in Chicago and Pfizer in New York City. He also founded a New York City theatre and sightseeing business, Manfreakinhattan. Scott has a Bachelor of Science in Chemistry and Psychology from Indiana University and a MBA from the Asian Institute of Management.

John London Chairman, Board of Directors & Co-Founder

John London's inspiration for co-founding Solving Kids' Cancer belongs solely to his daughter, Penelope, who once told him "I want no one to feel yucky Daddy". The mission of his life is to make sure that no other children and families suffer the loss his family has had to endure with Penelope's passing.

As Chairman of the Board of Directors, John's primary responsibilities with SKC include leadership and overall management of organizational governance, compliance, donor cultivation, and fundraising. John also serves as a strategic advisor in all areas of therapeutic development.

John also co-founded and currently serves as general partner for SuttonBrook Capital Management, an investment fund based in New York City. He has an MBA from The Wharton School of Business, University of Pennsylvania and a Bachelor of Arts from Brown University.

David Blaustein, MD
Chief Scientific Officer

Dr. Blaustein's role as Chief Scientific Advisor for SKC includes working with its scientific advisory board and Therapeutic Development Initiative (TDI) advisory group to provide overall scientific strategy and direction for the organization. He plays an integral role in identifying and investigating new therapies relevant to SKC's mission. He was instrumental in helping design SKC's entrepreneur-based TDI model. His unusual background, combining medicine, academia and business gives him a unique perspective on how to successfully apply entrepreneurial practices to traditional scientific research models, develop novel partnerships and foster innovation.

Dr. Blaustein also serves as a managing director at SuttonBrook Capital Management, a New York-based investment fund. Prior to his work in the financial industry, Dr. Blaustein served as an assistant professor of medicine and surgery at Yale University School of Medicine. He received his MBA from The Wharton School of Business, University of Pennsylvania, and his MD from the Weill Medical College, Cornell, New York.

Kenneth J. Cohen, MD, MBA
Solving Kids Cancer (TDI) Executive Officer
Associate Professor, Oncology and Pediatrics, Johns Hopkins University

Dr. Cohen serves on SKC's scientific advisory board, where he helps define the organization's scientific approach and research priorities. Additionally, as an Executive Officer of the TDI advisory board he is actively involved in the daily operations of the TDI including the grants solicitation and review process.

He is currently the Director of Pediatric Neuro-Oncology and the Clinical Director in the Division of Pediatric Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital. He joined the faculty at Johns Hopkins in 1994, after completing his Pediatric Hematology/Oncology Fellowship. The Pediatric Neuro-Oncology program's major focus is the development and testing of novel therapeutics for children with brain tumors. Research is also coordinated with the neuropsychology group at the Kennedy-Krieger Institute.

He serves as the co-chair of the High-Grade Glioma committee for the Children's Oncology Group where his focus is the development of therapeutics for the treatment of infiltrating gliomas. Dr. Cohen is a scientific advisor for the Childhood Brain Tumor Foundation. He received his undergraduate degree at Brown University and his MD from the State University of New York Upstate Medical Center in 1987. He completed his residency and Chief Residency in Pediatrics at the University Of Colorado School of Medicine in 1991.

###